Ruxolitinib Reverses Aberrations in STAT3 Gain-of-Function Disease
The following is a summary of “Ruxolitinib treatment ameliorates clinical, immunologic, and transcriptomic aberrations in patients with STAT3 gain-of-function disease,” published in the March 2025 issue of Journal of Allergy and Clinical Immunology by Catak et al. ...